Is vaccination coverage a good indicator of age-appropriate vaccination? A prospective study from Uganda
Peer reviewed, Journal article
MetadataShow full item record
Background: Timely vaccination is important to protect children from common infectious diseases. We assessed vaccination timeliness and vaccination coverage as well as coverage of vitamin A supplementation in a Ugandan setting. Methods and findings: This study used vaccination information gathered during a cluster-randomized trial promoting exclusive breastfeeding in Eastern Uganda between 2006 and 2008 (ClinicalTrials.gov no. NCT00397150). Five visits were carried out from birth up to 2 years of age (median follow-up time 1.5 years), and 765 children were included in the analysis. We used Kaplan–Meier time-to-event analysis to describe vaccination coverage and timeliness. Vaccination coverage at the end of follow-up was above 90% for all vaccines assessed individually that were part of the Expanded Program on Immunization (EPI), except for the measles vaccine which had 80% coverage (95%CI 76–83). In total, 75% (95%CI 71–79) had received all the recommended vaccines at the end of follow-up. Timely vaccination according to the recommendations of the Ugandan EPI was less common, ranging from 56% for the measles vaccine (95%CI 54–57) to 89% for the Bacillus Calmette–Guérin (BCG) vaccine (95%CI 86–91). Only 18% of the children received all vaccines within the recommended time ranges (95%CI 15–22). The children of mothers with higher education had more timely vaccination. The coverage for vitamin A supplementation at end of follow-up was 84% (95%CI 81–87). Conclusions: Vaccination coverage was reasonably high, but often not timely. Many children were unprotected for several months despite being vaccinated at the end of follow-up. There is a need for continued efforts to optimise vaccination timeliness.
CopyrightCopyright 2011 Elsevier Ltd.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Showing items related by title, author, creator and subject.
Cost-Effectiveness of Vaccination of Older Adults with an MF59®-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden Jacob, Jorge; Biering-Sørensen, Tor; Holger Ehlers, Lars; Edwards, Christina Hansen; Mohn, Kristin Greve-Isdahl; Nilsson, Anna; Hjelmgren, Jonas; Ma, Wenkang; Sharma, Yuvraj; Ciglia, Emanuele; Mould-Quevedo, Joaquin (Journal article; Peer reviewed, 2023)Individuals aged 65 years and above are at increased risk of complications and death from influenza compared with any other age group. Enhanced vaccines, as the MF59®-adjuvanted quadrivalent influenza vaccine (aQIV) and ...
Sridhar, Saranya; Brokstad, Karl Albert; Cox, Rebecca Jane (Peer reviewed; Journal article, 2015-04-24)Influenza is a major respiratory pathogen causing annual outbreaks and occasional pandemics. Influenza vaccination is the major method of prophylaxis. Currently annual influenza vaccination is recommended for groups at ...
Live Attenuated Influenza Vaccine (LAIV) Immunization in Children and Adults: Lesson for Development of Universal Influenza Vaccine Islam, Shahinul (Doctoral thesis, 2019-11-06)According to the WHO (World Health Organization), one billion peoples are infected annually of whom three to five millions become severely ill and 250-500 000 deaths worldwide (He, Wang et al. 2013) although the latest ...